Compare FSUN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | PGEN |
|---|---|---|
| Founded | 1892 | 1998 |
| Country | United States | United States |
| Employees | 1186 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | FSUN | PGEN |
|---|---|---|
| Price | $36.05 | $4.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $45.00 | $8.33 |
| AVG Volume (30 Days) | 152.5K | ★ 4.9M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $79.34 | $1,115.92 |
| Revenue Next Year | $14.67 | $81.04 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.95 | $1.40 |
| 52 Week High | $42.34 | $5.47 |
| Indicator | FSUN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 64.27 |
| Support Level | $34.32 | $3.96 |
| Resistance Level | $37.12 | $5.06 |
| Average True Range (ATR) | 0.94 | 0.29 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 58.84 | 94.24 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.